Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 54,988 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more

Conditions: Endotracheal Intubation, Supraglottic Airway
Interventions: i-gel airway (Intersurgical Ltd., Wokingham, England), Laryngeal Mask Airway-Unique; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Asthma
Interventions: Asthma teaching in ER, Smartphone Asthma Control; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 4 Years to 11 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV, HIV Infections
Interventions: Energex HemoModulator; Device
Lead sponsor: Energex Systems, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Vulvovaginal Signs and Symptoms
Interventions: Votiva device; Device
Lead sponsor: InMode MD Ltd.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Timeline: 2020
U.S. locations: 2
States / cities: Hilton Head Island, South Carolina • Lubbock, Texas

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D; Drug
Lead sponsor: Amany Keruakous, MD, MS.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Cesarean Section
Interventions: 0.5% ropivacaine, 0.9% sodium chloride; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Colorectal Cancer
Interventions: capecitabine; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 90
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Recurrent Malignant Glioma
Interventions: IL13-PE38QQR; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 3 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: WHIM Syndrome
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: San Diego, California • Thousand Oaks, California • Iowa City, Iowa + 3 more

Conditions: Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions: Angiomax (bivalirudin); Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer
Interventions: Offering Additional Resources to Promote Symptom Management; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acquired Immunodeficiency Syndrome, HIV
Interventions: Provider Visit Incentive (PVI), Incentive Choice (IC); Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Illicit Opioid Drug Use
Interventions: Linkage, Treatment as Usual; Behavioral · Other
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Fall River, Massachusetts

Conditions: Androgenetic Alopecia, Telogen Effluvium, Alopecia Areata
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Peripheral Neuropathy
Interventions: MIRE, Sham Device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Low Back Pain
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Suicidal Ideation, Suicidal Behavior, Mental Health Symptoms, Mental Health Hospitalizations
Interventions: Actigraph; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Breast Cancer
Interventions: filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody BrE-3, yttrium Y 90 monoclonal antibody BrE-3; Biological · Procedure · Radiation
Lead sponsor: Cancer Research Institute of Contra Costa; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Irritable Bowel Syndrome
Interventions: Standard Acupuncture/Moxibustion (fixed protocol), Individualized Acupuncture/Moxibustion, Sham/Placebo Acupuncture/Moxibustion; Other
Lead sponsor: New York University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Untreated Adult Acute Myeloid Leukemia
Interventions: Cytarabine, Decitabine, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 60 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 9
States / cities: Bozeman, Montana • Kennewick, Washington • Kirkland, Washington + 6 more

Conditions: Colorectal Cancer
Interventions: vitamin E, laboratory biomarker analysis; Dietary Supplement · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Wellesley, Massachusetts • Cleveland, Ohio + 2 more

Search by objective public record fields.

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Comparison of I-gel to the Laryngeal Mask Airway

Smartphone-facilitated Asthma Control

Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)

Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor

Retrospective Chart Review Study of Patients Treated With Votiva Device

VitD3 Supplementation in Patients With Multiple Myeloma

Pain Relief Study of Ultrasound Guided Transverse Abdominis Plane(TAP)Block

S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

A Commitment Device for Medication Adherence Among HIV Patients

Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care

PAI-1 Expression in Non-scarring Hair Loss

Near Infrared Light for the Treatment of Painful Peripheral Neuropathy

Effect of Milnacipran in Chronic Neuropathic Low Back Pain

The "AIM Study": Investigating Whether Actigraphy and Ideation Measures Can Promote Patient Safety

Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)